Results from the Phase II SWOG-S1117 Trial in Higher-Risk MDS and CMML and the Phase III MDS-005 Trial in Lower-Risk MDS without del(5q)


Results from the Phase II SWOG-S1117 Trial in Higher-Risk MDS and CMML and the Phase III MDS-005 Trial in Lower-Risk MDS without del(5q)
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Mikkael A Sekeres, MD, MS (1/20/15)
Sekeres MA et al. A randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup study SWOG S1117. Proc ASH 2014;Abstract LBA-5.

Santini V et al. Efficacy and safety of lenalidomide (LEN) versus placebo (PBO) in RBC-transfusion dependent (TD) patients (Pts) with IPSS low/intermediate (Int-1)-risk myelodysplastic syndromes (MDS) without del(5q) and unresponsive or refractory to erythropoiesis-stimulating agents (ESAs): Results from a randomized phase 3 study (CC-5013-MDS-005). Proc ASH 2014;Abstract 409.

Dr Sekeres is Professor of Medicine and Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio.